Cingulate

We're proud to be featured in @TheStreet, highlighting Cingulate, CEO Shane @shanejschaf and our Precision Timed Release™ (PTR™) platform. Learn how we're advancing innovation in ADHD treatment: thestreet.com/crypto/newsroo… #ADHD #Biotech

Exciting News from Cingulate: We’ve received a $4.3M PDUFA fee waiver from the FDA ahead of our imminent NDA submission for CTx-1301, our lead asset for the treatment of ADHD. Learn more: finance.yahoo.com/news/cingulate… #CTx1301 #ADHD #FDA #PDUFA #NDA #CING #PrecisionTimedRelease #PTR

Zacks analyst John Vandermosten recently spotlighted CING in his “Summer of Submissions,” regarding our planned NDA submission later this month. Watch the full video here and see why we’re on the radar: 📺 lnkd.in/gM7KrXVb #CING #NASDAQ #CTx1301 #NDA #ADHD #FDA #Zacks

We’re excited to welcome Nilay Patel, JD as our Chief Legal Officer! Nilay brings deep legal expertise and a strategic understanding of the complexities of pharma commercialization. #PharmaLaw #ADHD #Cingulate #Innovation #CING #Nasdaq #ADHDtreatment finance.yahoo.com/news/cingulate…

📢 Stonegate Capital Partners has initiated coverage on Cingulate (NASDAQ: CING) with a valuation range of $13.96–$26.96. Read the announcement and full report: finance.yahoo.com/news/stonegate… #CING #ADHD #CTX1301 #NDASubmission #StonegateCapitalPartners

#ICMYI: Congress held a key hearing this week on strengthening U.S. manufacturing and supply chain security. 🇺🇸 youtube.com/watch?v=eXkAOK… CING proudly supports onshoring and ensuring patient access to ADHD meds. #adhd #cing #SupplyChainSecurity #onshoring

#ICMYI Cingulate CEO Shane Schaffer outlines CING’s plans to commercialize CTx-1301 and explains why Indegene is the perfect partner to bring CING’s lead ADHD asset to market. #Cingulate #CING #Commercialization #ADHD youtube.com/watch?v=JLfjj5…

What does an ADHD diagnosis mean to you? Cingulate CEO Shane Schaffer explores the wide spectrum of those living with ADHD and the unique paths they take on their journey. #ADHD #CING #Cingulate #Nasdaq youtu.be/-MPXRIvbvwY

#ICYM : Cingulate announced phase 3 pediatric efficacy results for CTX-1301. CEO Shane Schaffer joined Zacks analyst John Vandermosten on the Unboxing Biotechpodcast. #Cingulate #biotech #efficacyresults #CING #Nasdaq youtu.be/trHIjzvRAvs

Business Development and Licensing joins our CEO to discuss Cingulate's strategic roadmap. #BusinessDevelopment #Licensing #Cingulate #CingulateInc #StrategicRoadmap #PharmaStrategy youtu.be/9hxJeZWg6kE

How Did Cingulate Begin? CEO Shane Schaffer Shares the Story. #CING #ADHD #CompanyOrigins #PharmaInnovation #Biotech #CEOInsights #Cingulate youtu.be/5vAWMCb5VMg

Inside Cingulate: A Conversation with the Board of Directors. #BoardOfDirectors #ExecutiveLeadership #Cingulate #CING #NASDAQ #Corporateinsights youtu.be/tRLD7RTELd8

Behind Closed Doors: Big Biz Show Gets Inside Look at Cingulate Board Meeting. #BigBizShow #Cingulate #CingulateNews #InsideCingulate #BigBizExclusive youtu.be/_eOP5k6wnaU

CEO Shane Schaffer recently shared insights at the 2025 Roth Conference with Big Biz Show Analyst Howie Font, including investor sentiment, near-term milestones, and the future of PTR. #rothconference #investors#FutureGrowth #PTR #BigBiz youtu.be/wbBPPaBEbUE

Overcoming the Unmet Needs of ADHD: Cingulate CEO Shane Schaffer Discusses the Safety Profile of CTx-1301 and more on the Big Biz Show. #adhd #cingulate #cingulate #NASDAQ youtu.be/KewFI7asRTc

Why are stimulants the most effective way of treating ADHD? The Science Behind ADHD Treatment: Cingulate Inc.'s CEO Shane Schaffer and CMO Matthew Brams on the Big Biz Show. #ADHD #CING #Cingulate #Stimulants #Treatment youtu.be/WaJlMpOtjFw?si…

What does entire active day coverage mean to you? CEO Shane Schaffer discusses Cingulate’s lead ADHD asset CTx-1301 with life sciences analyst John Vandermosten below. youtube.com/watch?v=K-pdLT… #ADHD #CING #Cingulate #nasdaq

Cingulate CEO Shane Schaffer recently sat down with “Unboxing Biotech” host John Vandermosten for a wide-ranging interview. In this excerpt Schaffer maps out CING’s timeline to NDA submission for lead ADHD asset CTx-1301. #adhd #CING #Nasdaq #Cingulate youtube.com/watch?v=qiWp2f…

CING CEO Shane Schaffer recently joined the Big Biz Show in-studio to discuss the genesis of CING and the evolution of its Precision Timed Release™ drug delivery platform. Watch part one of the interview here. youtu.be/I61s2TISXwo #adhd #cing #cingulate #adhdawareness

Cingulate's Shane Schaffer went LIVE in studio with the Big Biz Show. A shout-out to Sully & crew for their amazing hospitality and continued interest in CING! Visit cingulate.com for updates! #cingulate #adhd #cing #adhdawareness youtu.be/qZrI3iPzpSQ